Skip to main content

Therapeutic potential of optimized derivatives of an endogenous CXCR4 antagonist for the treatment of cancers and inflammatory diseases

Project description

Novel drugs against cancer and inflammatory diseases

CXCR4 is a chemokine receptor implicated in several pathological conditions including cancer and viral infections. It is activated by CXCL12, which regulates cell adhesion to stroma and hematopoietic stem cell mobilisation, and also serves as a co-receptor for HIV entry into cells. The aim of the EU-funded EPI-X4Health project is to test the endogenous peptide EPI-X4 for its therapeutic potential against cancer and inflammatory diseases. EPI-X4 is a human serum albumin derivative previously identified by the scientific team to inhibit HIV. Researchers will screen new synthetic derivatives of EPI-X4 in animal models of disease.

Host institution

UNIVERSITAET ULM
Net EU contribution
€ 95 256,00
Address
Helmholtzstrasse 16
89081 Ulm
Germany

See on map

Region
Baden-Württemberg Tübingen Ulm, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00

Beneficiaries (3)

UNIVERSITAET ULM
Germany
Net EU contribution
€ 95 256,00
Address
Helmholtzstrasse 16
89081 Ulm

See on map

Region
Baden-Württemberg Tübingen Ulm, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Germany
Net EU contribution
€ 26 950,00
Address
Hansastrasse 27c
80686 Munchen

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Other funding
€ 0,00
UNIVERSITE DE STRASBOURG
France
Net EU contribution
€ 26 950,00
Address
Rue Blaise Pascal 4
67081 Strasbourg

See on map

Region
Grand Est Alsace Bas-Rhin
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00